Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL
Poorvi H. Dua, Bazilco M.J. Simon, Chiara B.E. Marley, Carissa M. Feliciano, Hannah L. Watry, Quinn T. Cowan, Dylan Steury, Abin Abraham, Erin N. Gilbertson, Grace D. Ramey, John A. Capra, Bruce R. Conklin, Luke M. Judge
This paper demonstrates haplotype editing with CRISPR/Cas9 to target NEFL missense mutations in iPSC-derived motor neurons, showing therapeutic potential and challenges in disrupting mutant allele expression.
Molecular Therapy · Nov 20, 2025Peer-reviewedGenetics